hPRL-G129R

Drug Profile

hPRL-G129R

Latest Information Update: 20 Jul 2006

Price : $50

At a glance

  • Originator Clemson University; Greenville Hospital System
  • Class Anterior pituitary hormones; Antineoplastics; Pituitary gonadotropins
  • Mechanism of Action Apoptosis stimulants; Prolactin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 20 Jul 2006 No development reported - Preclinical for Breast cancer in USA (unspecified route)
  • 18 Jun 2002 A preclinical study has been added to the Cancer pharmacodynamics section
  • 07 Mar 2000 Preclinical data have been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top